Shire
SHP
Real-time BATS EUROPE - 09/21 05:30:00 pm
4560.25GBp
+1.22%
Prev.4509.0000
Open4499.5000
High4571.0000
Low4499.5000
Volume2 268 092
Financials
Sales 2018 15 529 M
EBIT 2018 5 897 M
R. net 2018 2 730 M
Debt 2018 15 198 M
Rend. 2018 0,60%
P/E ratio 2018 18,54
P/E ratio 2019 16,07
EV / Sales 2018 4,47x
EV / Sales 2019 4,11x
Capitalization 54 200 M
Company
Shire Plc is a biopharmaceutical company.It engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of medicines to meet significant unmet patient needs.The company's products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin,...
Sector :
Pharmaceuticals - NEC
Calendar :
2018-10-25 Earnings Release
Trading Rating :
Investor Rating :
Latest news
01:09pSHIRE : Form 8.3 - Takeda Pharmaceutical Company Limited
PU
12:19pSHIRE : Form 8.5 (EPT/RI) - SHIRE PLC
PU
11:44aSHIRE : Form 8.3 - Shire plc
PU
11:04aMERRIMACK PHARMACEUTICALS : Receives $5 Million Milestone Payment from Shire
AQ
08:15aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
08:14aSHIRE : Receives Approval of FIRAZYR(R) (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan
PU
08:09aSHIRE PLC : Rule 2.9 Announcement
PU
08:00aSHIRE : Receives Approval of FIRAZYRŪ (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralBullishBullish
Resistance4 5624 5624 513
Spread/Res.0,15%0,15%1,2%
Spread/Supp.7,1%23%23%
Support4 2653 7093 709